We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Registry to Gather Long-time Results After Surgical Aortic Valve Replacement With a "Rapid Deployment Aortic Valve Prothesis (Edwards Intuity) Combined With Bypss Surgery (CABG) (INCA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03326778
Recruitment Status : Completed
First Posted : October 31, 2017
Last Update Posted : August 26, 2021
Sponsor:
Collaborators:
Edwards Lifesciences
Software for Trials Europe GmbH
Institut für Pharmakologie und Präventive Medizin
Information provided by (Responsible Party):
Campus Bad Neustadt

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a prospctive, unrandomized multicentric registry which will enrol patients with an indication for aortc valve replacement combined with myocardial reperfusion (CABG). The registry will collect patient specific baseline data and established risk scores (Logistic Euroscore I & II, STS-Score, KBA Score) to enable us to make an estimate about the perioperative risks.

Condition or disease Intervention/treatment
Aortic Valve Stenosis Coronary Artery Disease Procedure: AVR and CABG

Detailed Description:

Aortic replacement combined with coronary bypass surgery has an impact on the risk profile for the direct postoperative course and also on the long-time survival perspective.

The advantage of rapid deployment aortic valve prostheses, like the Edward Intuity Elite Valve that is used in this registry, is the greater ease of implantation, because only a few sutures are necessary to secure the device compared to a conventional prosthesis, where more then ten sutures are needed. In procedures where the aortic valve replacement (AVR) is combined with a coronary artery bypass graft (CABG), the use of a rapid deployment valve can shorten the duration of cardiac ischemia and the overall intervention duration, which possibly has an influence on clinical results.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 220 participants
Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: Register Zur Erhebung Von Langzeitergebnissen Nach Chirurgischem Aortenklappen Ersatz Mit Einer "Rapid Deployment" Aortenklappenprothese (Edwards Intuity) in Kombination Mit Einer Bypassoperation (CABG)
Actual Study Start Date : November 26, 2017
Actual Primary Completion Date : December 6, 2019
Actual Study Completion Date : July 1, 2020

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
AVR + CABG
Patient receiving AVR combined with CABG
 Procedure: AVR and CABG
Combined AVR with CABG


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. all-cause mortality [ Time Frame: 30 Days ]
    death from any reason


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with an indication for AVR combined with CABG who will receive an Edwards Intuity Elite rapid deployment aortic valve prosthesis.
Criteria

Inclusion Criteria:

  • Inclusion Criteria:
  • patients with aortic valve stenosis and coronary heart disease with indication for AVR and CABG
  • patients in who the Edwards Intuity Elite valve is to be implanted
  • patients who are planned to receive at least one coronary bypass
  • patients who have signed an informed consent form

Exclusion Criteria:

  • Exclusion Criteria:
  • emergency surgery
  • re-operation (i.e. any previous opening of pericardium)
  • additional heart diseases requiring heart surgery (e. g. subvalvular myectomy and ablation, but not atrial auricle closure or resection)
  • legal incapacity or other circumstances that impair the patient's ability to understand the nature, meaning or extent of the trial
  • patients wanting a mechanical prosthesis
  • patients with contraindications for the Edwards Intuity Elite Valve
  • acute endocarditis or other systemic infections
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03326778


Locations
Layout table for location information
Germany
Campus Bad Neustadt
Bad Neustadt An Der Saale, Bavaria, Germany, 97616
Sponsors and Collaborators
Campus Bad Neustadt
Edwards Lifesciences
Software for Trials Europe GmbH
Institut für Pharmakologie und Präventive Medizin
Investigators
Layout table for investigator information
Principal Investigator: Anno Diegeler, Prof. Campus Bad Neustadt
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Campus Bad Neustadt
ClinicalTrials.gov Identifier: NCT03326778    
Other Study ID Numbers: INCA
First Posted: October 31, 2017    Key Record Dates
Last Update Posted: August 26, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Campus Bad Neustadt:
Aortic Valve Stenosis
Rapid deployment Valve
CABG
Edwards Intuity Elite
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Aortic Valve Stenosis
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
 Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Aortic Valve Disease
Heart Valve Diseases
Ventricular Outflow Obstruction